Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-3927 in Propionic Acidemia
NCT04159103Phase 2Recruiting
- Sponsor
- Moderna Inc
- Start
- Apr 2021
- Primary completion
- Aug 2027
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 8
01
Overview
Phase 2, open-label trial of mRNA-3927 in propionic acidemia (PA) (3 arms), sponsored by Moderna Inc. Primary endpoints: Treatment-emergent Adverse Event at 150 weeks and Annualized Frequency of Metabolic Decompensation Events at 12 months. Started Apr 2021; status: recruiting.
02
Drugs
mRNA-3927
03
Conditions
propionic acidemia (PA)
Beyond the preview
Go deeper on NCT04159103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04159103.